Homeostatic Model Assessment of β-cell Function May be an Emerging Predictor of Bone Resorption in Metabolically Unhealthy Obesity
Abstract
Objectives: The aim of this study is to compare three distinct bone markers in metabolically healthy and unhealthy obese and non-obese subjects, according to various metabolic health criteria.
Methods: The study enrolled a total of 35 subjects, including 11 healthy normal-weight and 23 obese subjects. Based on HOMA-Beta, all participants were divided into three groups: normal weight (HOM-Beta<100%, n=11), obese (HOMA-Beta <100%, n=12), and obese (HOMA-Beta>100%, n=12). The serum levels of osteocalcin, procollagen I amino-terminal propeptide (P1NP), and beta-cross Laps as bone turnover markers, as well as serum levels of 25 (OH) vitamin D3, and PTH were analyzed.
Results: Significant differences were observed in BMI, age, 25(OH)D3, FBS, Insulin, HOMAIR, and HOMA-Beta among the groups. Analysis of bone markers revealed that the serum levels of Beta-cross Laps, P1NP, and osteocalcin were significantly different among all studied groups categorized by the HOMA-Beta model. In this context, circulating levels of osteocalcin and Betacross Laps in the normal weight group (HOMA-Beta<100%) were significantly higher than the obese group (HOMA-Beta <100%). In obese patients with HOMA-Beta <100%, Beta-cross Laps and P1NP levels were lower compared to the obese group with HOMA-Beta >100%.
Conclusion: The data suggests that HOMA-Beta, as an index of β-cell function, can be used in part of metabolically healthy obese (MHO) criteria and bone remodeling is altered in the context of metabolically healthy obesity.
References
1. Poulos, S.P., D.B. Hausman, and G.J. Hausman, The development and endocrine functions of adipose tissue. Mol Cell Endocrinol, 2010. 323(1): p. 20-34.
2. Harwood, H.J., Jr., The adipocyte as an endocrine organ in the regulation of metabolic homeostasis. Neuropharmacology, 2012. 63(1): p. 57-75.
3. Cao, J.J., Effects of obesity on bone metabolism. J Orthop Surg Res, 2011. 6: p. 30.
4. Zhao, L.J., Y.J. Liu, P.Y. Liu, J. Hamilton, R.R. Recker, and H.W. Deng, Relationship of obesity with osteoporosis. J Clin Endocrinol Metab, 2007. 92(5): p. 1640-6.
5. Greco, E.A., A. Lenzi, and S. Migliaccio, The obesity of bone. Ther Adv Endocrinol Metab, 2015. 6(6): p. 273-86.
6. Gomez-Ambrosi, J., A. Rodriguez, V. Catalan, and G. Fruhbeck, The bone-adipose axis in obesity and weight loss. Obes Surg, 2008. 18(9): p. 1134-43.
7. Kawai, M., F.J. de Paula, and C.J. Rosen, New insights into osteoporosis: the bone-fat connection. J Intern Med, 2012. 272(4): p. 317-29.
8. Rosen, C.J. and A. Klibanski, Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med, 2009. 122(5): p. 409-14.
9. Brown, J.P., A. Don-Wauchope, P. Douville, C. Albert, and S.D. Vasikaran, Current use of bone turnover markers in the management of osteoporosis. Clin Biochem, 2022. 109-110: p. 1-10.
10. Vasikaran, S.D., M. Miura, R. Pikner, H.P. Bhattoa, and E. Cavalier, Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis. Calcif Tissue Int, 2023. 112(2): p. 148-157.
11. Iglesias, P., F. Arrieta, M. Pinera, J.I. Botella-Carretero, J.A. Balsa, I. Zamarron, et al., Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. Clin Endocrinol (Oxf), 2011. 75(2): p. 184-8.
12. Peichl, P., A. Griesmacherb, R. Marteau, S. Hejc, W. Kumpan, M.M. Muller, et al., Serum crosslaps in comparison to serum osteocalcin and urinary bone resorption markers. Clin Biochem, 2001. 34(2): p. 131-9.
13. Brandão, I., M.J. Martins, and R. Monteiro, Metabolically Healthy Obesity-Heterogeneity in Definitions and Unconventional Factors. Metabolites, 2020. 10(2).
14. Smith, G.I., B. Mittendorfer, and S. Klein, Metabolically healthy obesity: facts and fantasies. J Clin Invest, 2019. 129(10): p. 3978-3989.
15. Tanriover, C., S. Copur, A. Gaipov, B. Ozlusen, R.E. Akcan, M. Kuwabara, et al., Metabolically healthy obesity: Misleading phrase or healthy phenotype? Eur J Intern Med, 2023. 111: p. 5-20.
16. Dimitri, P., J.K. Wales, and N. Bishop, Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. Bone, 2011. 48(2): p. 189-96.
17. Evans, A.L., M.A. Paggiosi, R. Eastell, and J.S. Walsh, Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood. J Bone Miner Res, 2015. 30(5): p. 920-8.
18. Nima Taghizadeh , S.M., Vahid Saeedi, Ladan Haghighi, Mona Nourbakhsh, Mitra Nourbakhsh, Maryam Razzaghy Azar, Association between Steroid Hormones and Insulin Resistance in Patients with Polycystic Ovary Syndrome. Acta Biochimica Iranica, 2023. 1(1): p. 26-31.
19. Hamzeh Saberi , G.T., Reza Meshkani The ENPP1 K121Q polymorphism is associated with obesity-related parameters in Iranian normoglycemic male subjects. Acta Biochimica Iranica, 2023. 1(1): p. 20-25.
20. Holecki, M. and A. Wiecek, Relationship between body fat mass and bone metabolism. Pol Arch Med Wewn, 2010. 120(9): p. 361-7.
21. Hong, H.C., J.S. Lee, H.Y. Choi, S.J. Yang, H.J. Yoo, J.A. Seo, et al., Liver enzymes and vitamin D levels in metabolically healthy but obese individuals: Korean National Health and Nutrition Examination Survey. Metabolism, 2013. 62(9): p. 1305-12.
22. Esteghamati, A., Z. Aryan, and M. Nakhjavani, Differences in vitamin D concentration between metabolically healthy and unhealthy obese adults: associations with inflammatory and cardiometabolic markers in 4391 subjects. Diabetes Metab, 2014. 40(5): p. 347-55.
23. Park, S.Y., J.F. Gautier, and S. Chon, Assessment of Insulin Secretion and Insulin Resistance in Human. Diabetes Metab J, 2021. 45(5): p. 641-654.
24. Tahapary, D.L., L.B. Pratisthita, N.A. Fitri, C. Marcella, S. Wafa, F. Kurniawan, et al., Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride/glucose index. Diabetes Metab Syndr, 2022. 16(8): p. 102581.
25. Wallace, T.M., J.C. Levy, and D.R. Matthews, Use and abuse of HOMA modeling. Diabetes Care, 2004. 27(6): p. 1487-95.
26. Ahren, B. and G. Pacini, Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol, 2004. 150(2): p. 97-104.
27. Zahra Barmoudeh , M.H.S., Hossein Pourghadamyari, Mina Rohani Borj , Amir Hossein Doustimotlagh, Kazem Abbaszadeh-Goudarzi, C1q tumor necrosis factor related proteins (CTRPs) in patients with cardiovascular diseases. Acta Biochimica Iranica, 2023. 1(1): p. 12-19.
28. Samuel, V.T. and G.I. Shulman, The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest, 2016. 126(1): p. 12-22.
29. Schinner, S., W.A. Scherbaum, S.R. Bornstein, and A. Barthel, Molecular mechanisms of insulin resistance. Diabet Med, 2005. 22(6): p. 674-82.
30. Manrique, C., G. Lastra, and J.R. Sowers, New insights into insulin action and resistance in the vasculature. Ann N Y Acad Sci, 2014. 1311: p. 138-50.
1. Poulos, S.P., D.B. Hausman, and G.J. Hausman, The development and endocrine functions of adipose tissue. Mol Cell Endocrinol, 2010. 323(1): p. 20-34.
2. Harwood, H.J., Jr., The adipocyte as an endocrine organ in the regulation of metabolic homeostasis. Neuropharmacology, 2012. 63(1): p. 57-75.
3. Cao, J.J., Effects of obesity on bone metabolism. J Orthop Surg Res, 2011. 6: p. 30.
4. Zhao, L.J., Y.J. Liu, P.Y. Liu, J. Hamilton, R.R. Recker, and H.W. Deng, Relationship of obesity with osteoporosis. J Clin Endocrinol Metab, 2007. 92(5): p. 1640-6.
5. Greco, E.A., A. Lenzi, and S. Migliaccio, The obesity of bone. Ther Adv Endocrinol Metab, 2015. 6(6): p. 273-86.
6. Gomez-Ambrosi, J., A. Rodriguez, V. Catalan, and G. Fruhbeck, The bone-adipose axis in obesity and weight loss. Obes Surg, 2008. 18(9): p. 1134-43.
7. Kawai, M., F.J. de Paula, and C.J. Rosen, New insights into osteoporosis: the bone-fat connection. J Intern Med, 2012. 272(4): p. 317-29.
8. Rosen, C.J. and A. Klibanski, Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med, 2009. 122(5): p. 409-14.
9. Brown, J.P., A. Don-Wauchope, P. Douville, C. Albert, and S.D. Vasikaran, Current use of bone turnover markers in the management of osteoporosis. Clin Biochem, 2022. 109-110: p. 1-10.
10. Vasikaran, S.D., M. Miura, R. Pikner, H.P. Bhattoa, and E. Cavalier, Practical Considerations for the Clinical Application of Bone Turnover Markers in Osteoporosis. Calcif Tissue Int, 2023. 112(2): p. 148-157.
11. Iglesias, P., F. Arrieta, M. Pinera, J.I. Botella-Carretero, J.A. Balsa, I. Zamarron, et al., Serum concentrations of osteocalcin, procollagen type 1 N-terminal propeptide and beta-CrossLaps in obese subjects with varying degrees of glucose tolerance. Clin Endocrinol (Oxf), 2011. 75(2): p. 184-8.
12. Peichl, P., A. Griesmacherb, R. Marteau, S. Hejc, W. Kumpan, M.M. Muller, et al., Serum crosslaps in comparison to serum osteocalcin and urinary bone resorption markers. Clin Biochem, 2001. 34(2): p. 131-9.
13. Brandão, I., M.J. Martins, and R. Monteiro, Metabolically Healthy Obesity-Heterogeneity in Definitions and Unconventional Factors. Metabolites, 2020. 10(2).
14. Smith, G.I., B. Mittendorfer, and S. Klein, Metabolically healthy obesity: facts and fantasies. J Clin Invest, 2019. 129(10): p. 3978-3989.
15. Tanriover, C., S. Copur, A. Gaipov, B. Ozlusen, R.E. Akcan, M. Kuwabara, et al., Metabolically healthy obesity: Misleading phrase or healthy phenotype? Eur J Intern Med, 2023. 111: p. 5-20.
16. Dimitri, P., J.K. Wales, and N. Bishop, Adipokines, bone-derived factors and bone turnover in obese children; evidence for altered fat-bone signalling resulting in reduced bone mass. Bone, 2011. 48(2): p. 189-96.
17. Evans, A.L., M.A. Paggiosi, R. Eastell, and J.S. Walsh, Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood. J Bone Miner Res, 2015. 30(5): p. 920-8.
18. Nima Taghizadeh , S.M., Vahid Saeedi, Ladan Haghighi, Mona Nourbakhsh, Mitra Nourbakhsh, Maryam Razzaghy Azar, Association between Steroid Hormones and Insulin Resistance in Patients with Polycystic Ovary Syndrome. Acta Biochimica Iranica, 2023. 1(1): p. 26-31.
19. Hamzeh Saberi , G.T., Reza Meshkani The ENPP1 K121Q polymorphism is associated with obesity-related parameters in Iranian normoglycemic male subjects. Acta Biochimica Iranica, 2023. 1(1): p. 20-25.
20. Holecki, M. and A. Wiecek, Relationship between body fat mass and bone metabolism. Pol Arch Med Wewn, 2010. 120(9): p. 361-7.
21. Hong, H.C., J.S. Lee, H.Y. Choi, S.J. Yang, H.J. Yoo, J.A. Seo, et al., Liver enzymes and vitamin D levels in metabolically healthy but obese individuals: Korean National Health and Nutrition Examination Survey. Metabolism, 2013. 62(9): p. 1305-12.
22. Esteghamati, A., Z. Aryan, and M. Nakhjavani, Differences in vitamin D concentration between metabolically healthy and unhealthy obese adults: associations with inflammatory and cardiometabolic markers in 4391 subjects. Diabetes Metab, 2014. 40(5): p. 347-55.
23. Park, S.Y., J.F. Gautier, and S. Chon, Assessment of Insulin Secretion and Insulin Resistance in Human. Diabetes Metab J, 2021. 45(5): p. 641-654.
24. Tahapary, D.L., L.B. Pratisthita, N.A. Fitri, C. Marcella, S. Wafa, F. Kurniawan, et al., Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride/glucose index. Diabetes Metab Syndr, 2022. 16(8): p. 102581.
25. Wallace, T.M., J.C. Levy, and D.R. Matthews, Use and abuse of HOMA modeling. Diabetes Care, 2004. 27(6): p. 1487-95.
26. Ahren, B. and G. Pacini, Importance of quantifying insulin secretion in relation to insulin sensitivity to accurately assess beta cell function in clinical studies. Eur J Endocrinol, 2004. 150(2): p. 97-104.
27. Zahra Barmoudeh , M.H.S., Hossein Pourghadamyari, Mina Rohani Borj , Amir Hossein Doustimotlagh, Kazem Abbaszadeh-Goudarzi, C1q tumor necrosis factor related proteins (CTRPs) in patients with cardiovascular diseases. Acta Biochimica Iranica, 2023. 1(1): p. 12-19.
28. Samuel, V.T. and G.I. Shulman, The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux. J Clin Invest, 2016. 126(1): p. 12-22.
29. Schinner, S., W.A. Scherbaum, S.R. Bornstein, and A. Barthel, Molecular mechanisms of insulin resistance. Diabet Med, 2005. 22(6): p. 674-82.
30. Manrique, C., G. Lastra, and J.R. Sowers, New insights into insulin action and resistance in the vasculature. Ann N Y Acad Sci, 2014. 1311: p. 138-50.
| Files | ||
| Issue | Vol 1 No 2 (2023) | |
| Section | Original Articles | |
| DOI | https://doi.org/10.18502/abi.v1i2.14104 | |
| Keywords | ||
| HOMA-beta bone marker metabolically healthy obesity | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Emamgholipour S, Maghbooli Z, Talebpour M, Gorgani-Firuzjaee S, Shirvani A. Homeostatic Model Assessment of β-cell Function May be an Emerging Predictor of Bone Resorption in Metabolically Unhealthy Obesity. ABI. 2023;1(2):78-82.
